647 related articles for article (PubMed ID: 17973307)
1. Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: structure and degradation pathways.
Kerwin BA
J Pharm Sci; 2008 Aug; 97(8):2924-35. PubMed ID: 17973307
[TBL] [Abstract][Full Text] [Related]
2. Characterization of Polysorbate Ester Fractions and Implications in Protein Drug Product Stability.
Tomlinson A; Zarraga IE; Demeule B
Mol Pharm; 2020 Jul; 17(7):2345-2353. PubMed ID: 32442382
[TBL] [Abstract][Full Text] [Related]
3. Existence of a superior polysorbate fraction in respect to protein stabilization and particle formation?
Diederichs T; Mittag JJ; Humphrey J; Voss S; Carle S; Buske J; Garidel P
Int J Pharm; 2023 Mar; 635():122660. PubMed ID: 36740078
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization and assessment of suitability of trehalose fatty acid esters as alternatives for polysorbates in protein formulation.
Schiefelbein L; Keller M; Weissmann F; Luber M; Bracher F; Friess W
Eur J Pharm Biopharm; 2010 Nov; 76(3):342-50. PubMed ID: 20816956
[TBL] [Abstract][Full Text] [Related]
5. Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations.
Labrenz SR
J Pharm Sci; 2014 Aug; 103(8):2268-77. PubMed ID: 24942482
[TBL] [Abstract][Full Text] [Related]
6. The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics.
Kishore RS; Kiese S; Fischer S; Pappenberger A; Grauschopf U; Mahler HC
Pharm Res; 2011 May; 28(5):1194-210. PubMed ID: 21369824
[TBL] [Abstract][Full Text] [Related]
7. The composition of NF-defined emulsifiers: sorbitan monolaurate, monopalmitate, monostearate, monooleate, polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.
Brandner JD
Drug Dev Ind Pharm; 1998 Nov; 24(11):1049-54. PubMed ID: 9876559
[TBL] [Abstract][Full Text] [Related]
8. Free fatty acid particles in protein formulations, part 2: contribution of polysorbate raw material.
Siska CC; Pierini CJ; Lau HR; Latypov RF; Fesinmeyer RM; Litowski JR
J Pharm Sci; 2015 Feb; 104(2):447-56. PubMed ID: 25196966
[TBL] [Abstract][Full Text] [Related]
9. Improving Prediction of Free Fatty Acid Particle Formation in Biopharmaceutical Drug Products: Incorporating Ester Distribution during Polysorbate 20 Degradation.
Doshi N; Martin J; Tomlinson A
Mol Pharm; 2020 Nov; 17(11):4354-4363. PubMed ID: 32941040
[TBL] [Abstract][Full Text] [Related]
10. Poloxamer 188 as surfactant in biological formulations - An alternative for polysorbate 20/80?
Bollenbach L; Buske J; Mäder K; Garidel P
Int J Pharm; 2022 May; 620():121706. PubMed ID: 35367584
[TBL] [Abstract][Full Text] [Related]
11. Oxidative degradation of polysorbate surfactants studied by liquid chromatography-mass spectrometry.
Borisov OV; Ji JA; Wang YJ
J Pharm Sci; 2015 Mar; 104(3):1005-18. PubMed ID: 25581232
[TBL] [Abstract][Full Text] [Related]
12. Adsorption at air-water and oil-water interfaces and self-assembly in aqueous solution of ethoxylated polysorbate nonionic surfactants.
Penfold J; Thomas RK; Li PX; Petkov JT; Tucker I; Webster JR; Terry AE
Langmuir; 2015 Mar; 31(10):3003-11. PubMed ID: 25697294
[TBL] [Abstract][Full Text] [Related]
13. An in-depth examination of fatty acid solubility limits in biotherapeutic protein formulations containing polysorbate 20 and polysorbate 80.
Glücklich N; Dwivedi M; Carle S; Buske J; Mäder K; Garidel P
Int J Pharm; 2020 Dec; 591():119934. PubMed ID: 33059015
[TBL] [Abstract][Full Text] [Related]
14. Polysorbates versus Hydroxypropyl Beta-Cyclodextrin (HPβCD): Comparative Study on Excipient Stability and Stabilization Benefits on Monoclonal Antibodies.
Zhang H; Hong S; Tan SSK; Peng T; Goh LYH; Lam KH; Chow KT; Gokhale R
Molecules; 2022 Oct; 27(19):. PubMed ID: 36235038
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Polysorbate 80 Hydrolysis and Oxidation on the Aggregation of a Monoclonal Antibody.
Larson NR; Wei Y; Prajapati I; Chakraborty A; Peters B; Kalonia C; Hudak S; Choudhary S; Esfandiary R; Dhar P; Schöneich C; Middaugh CR
J Pharm Sci; 2020 Jan; 109(1):633-639. PubMed ID: 31758949
[TBL] [Abstract][Full Text] [Related]
16. Alkylsaccharides: circumventing oxidative damage to biotherapeutics caused by polyoxyethylene-based surfactants.
Maggio ET
Ther Deliv; 2013 May; 4(5):567-72. PubMed ID: 23647275
[TBL] [Abstract][Full Text] [Related]
17. Mixed-mode and reversed-phase liquid chromatography-tandem mass spectrometry methodologies to study composition and base hydrolysis of polysorbate 20 and 80.
Hewitt D; Alvarez M; Robinson K; Ji J; Wang YJ; Kao YH; Zhang T
J Chromatogr A; 2011 Apr; 1218(15):2138-45. PubMed ID: 20950816
[TBL] [Abstract][Full Text] [Related]
18. Characterization of polysorbate 80 with liquid chromatography mass spectrometry and nuclear magnetic resonance spectroscopy: specific determination of oxidation products of thermally oxidized polysorbate 80.
Hvattum E; Yip WL; Grace D; Dyrstad K
J Pharm Biomed Anal; 2012 Mar; 62():7-16. PubMed ID: 22260967
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous surface self-assembly in protein-surfactant mixtures: interactions between hydrophobin and ethoxylated polysorbate surfactants.
Tucker IM; Petkov JT; Penfold J; Thomas RK; Li P; Cox AR; Hedges N; Webster JR
J Phys Chem B; 2014 May; 118(18):4867-75. PubMed ID: 24738908
[TBL] [Abstract][Full Text] [Related]
20. Acidic and alkaline hydrolysis of polysorbates under aqueous conditions: Towards understanding polysorbate degradation in biopharmaceutical formulations.
Dwivedi M; Buske J; Haemmerling F; Blech M; Garidel P
Eur J Pharm Sci; 2020 Mar; 144():105211. PubMed ID: 31931121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
